Jim. Thank you,
to We proprietary of our great and our has of through walk candidates promise, you will believe key continue pipeline product programs. each I
designed or advantage is involved across BX-HX. multiple of payload this duocarmazine, Vobramitamab vobra solid deliver antigen's of of molecules BX duo a broad our types. tumors ADC duocarmycin in member to regulation. designed DNA-alkylating Vobra to the expressing is family duo, cytotoxic to is take a tumor expression immune BX-HX
an We continue ideal of to attributes the target. cancer BX-HX believe has
being is androgen II have chemotherapy. received X who other study regimen, no prior but to up previously patients targeted The containing agents TAMARACK conducted and in an mCRPC Phase access receptor taxane
study survival, or trial, rPFS. and are disease The dosed no for being in While events, to progression-free the endpoint continue be adverse survival. primary participants monitored participants longer is study's progression radiographic
the ESMO to XX the at immature. only they rPFS that XXXX September were interim additional as Given believe cutoff, had as presented change PSF of XX.X% Congress these X, accrue. estimates events data accrued the likely And are were because events medium July we results or immature, in
We hand expect no to have mature early XXXX. later median than rPFS in
well in future the of the competitive for potential vobra mCRPC, landscape factors, mCRPC, across a our duo will several for development allocation be on as including final portfolio, TAMARACK alternatives and as efficacy treatment vobra our partnering well review clinical safety Assessment in based we of as combination Until I/II efforts resource data Phase opportunities tumor study alternative development of dose complete mCRPC, assessment in the monotherapy development our lorigerlimab. the plus as paused types of we vobra duo duo. other for have opportunity
X Recall other that have clinical BX-HX. target molecules that we
inhibitor incorporating linker MGCXXX, which novel licensed based ADC SYNtecan E, we X is from Synaffix. investigational an topoisomerase payload, a The first,
enoblituzumab, Our second the molecule investigational directed is monoclonal antibody. BX-HX additional Fc-optimized
distinct with More vobra of another targeting duo. exatecan, targeting and that readily with I or MGCXXX incorporates escalation we early hydrospace based same dose tumor molecule MGCXXX believe alternate action utility. the variable study initiated a We specifically, their pathway in of and BX-HX. safety be for potentially We approach to to vobra the combines [ enhance the targeting complementary of regardless technology. different combination a this a mechanisms linker solid view a efficacy on We domain agents BX-HX BX-HX MGCXXX year ] as stages payload X and camper potentially cancers, vobra mechanism the beacon potential clinical duo MGCXXX different that or in remain with having potent tumors. address advanced for validated duo of is MGCXXX used payload. of with in confident Synaffix's the profiles, in contained clinically may and action Phase or patients of the The sequence
are investigator-sponsored, an in II cancer. Phase academic of Regarding collaborators the men enrolling study up enoblituzumab, XXX study HEAT prostate our to with randomized molecule this
bispecific tumor-infiltrating x TILs, abundant CTLA-X are our have lorigerlimab We such lymphocytes, tumor tetravalent preferential Next, which I'll you update cells, to DART blockade most on in dual or designed expressing on as PD-X molecule. microenvironment. PD-X lorigerlimab, the CTLA-X
We alone a in second-line are randomized lorigerlimab, versus and in chemotherapy combination patients. trial docetaxel enrolling CRPC naive LORIKEET the study, docetaxel clinical with Phase II of
on late or study total The anticipate year of the study study planned date. current a treated enrolled be XXX design endpoint XXXX XXX X:X A study and clinical We a primary half the study in to first of early participants to of providing study XXXX. more this in randomized than with of includes completing enrollment data the are update patients the rPFS.
incorporates and molecule CDX minimize bispecific MGDXXX release maintaining is activity a anti-tumor component designed our by next-generation CDX half-life. DART CDXXX dosing intermittent that syndrome cytokine through to while a cytolytic permitting longer
Recall positive Gilead relapsed that with the CDXXX dose during Phase study. of option is the ongoing MGDXXX at I or decision leukemia escalation study malignancies, patients hematologic in Phase to Our monodysplastic I myeloid MGDXXX including predefined syndromes. license acute and refractory points has
payload making an a X and progression target Synaffix's member cancer an FDA. family ADAMX targeting the an novel overexpressed attractive topoisomerase and We X ADC transmembrane the is for of treatment. linker it application proteins second cancers, genesis U.S. drug multifunctional our of and tumor to in investigational is antibody. based submitted is in cancer recently play new MGCXXX for that Type Adams MGCXXX multiple incorporating inhibitor ADAMX a role
for future submission. you about molecules potential to look forward additional calls. exploring IND additional are these we future I MGCXXX, more on molecules Beyond telling
sold us LLC, announced to an aggregate to few $XX company, we of million is MARGENZA, $XX fourth at of quarter closing, to and agreement payments we may end, is a expected The global up to receive rights sales as expected of subject additional which customary Therapeutics an transaction marketed quarter to privately in to million. TerSera milestone pursuant ago. the biopharmaceutical is closing conditions. after XXXX, close weeks held TerSera a Finally, pay margetuximab, to
TerSera We and going current during will to of substance fee on amendment pay forward. fourth behalf MARGENZA drug manufacture expect an million commercialization of XXXX, quarter partner to the $X our
on milestones assets researching in enabling for transaction, from to financial further Thank as our of us as well our our The all joining of product sharpen while advancing developing received pending recently wave key strengthen stage the clinical million $XXX today. focus early you next priorities candidates. stage the our position, Incyte, and margetuximab
transformed down a that Together, years pipeline company treatments. of building MARGENZA, we integrated proud with CEO early dedicated and approval XX we've particularly personally be President TZIELD will stepping robust As After advancement we've as to patients. achieved, ZYNYZ of treatments, our I'm FDA you what know, fully biotech truly to year. like a last into professionally. helping announced antibody-based nearly ideas it's and week therapeutics me immensely next and the and I of milestone MacroGenics, for
for comes This supporting period foundation. thoughtful transition. during development has the search a am a transition time diverse committed with at initiated solid and a promising to portfolio to ensure The seamless strongly a and Board MacroGenics and is positioned I financial a successor, my when company this
MacroGenics' ahead, future. Looking in confident I am
shareholders advancing our now Operator? and support I'm to the for and adviser want dedication. all my continuing alike. to partners our MacroGenics accomplish its be as creating an will team, in Our excited chapter. shareholders I next Board, that would questions. and pipeline, patients see to open and near-term look partnerships remain forward goals our unchanged: to call MacroGenics and value We I expanding for thank for happy the their our shareholder,
